Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Presentation entities : Veru inc. save search
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer
Published: 2021-12-08 (Crawled : 14:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.39%
H: 7.82%
C: 5.63%
presentation preclinical cancer breast cancer pre-clinical metastatic breast cancer
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
Published: 2021-12-08 (Crawled : 13:30) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.39%
H: 7.82%
C: 5.63%
presentation preclinical cancer breast cancer pre-clinical symposium metastatic breast cancer
Veru Announces Oral Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 ESMO Congress
Published: 2021-09-09 (Crawled : 13:15) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -1.31%
H: 5.75%
C: 3.73%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.33%
H: 0.06%
C: -1.44%
presentation prostate cancer phase 1 cancer phase 1b sabizabulin phase 2b
Veru to Present at Three Upcoming Healthcare Investment Conferences
Published: 2021-09-08 (Crawled : 14:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -1.08%
H: 1.63%
C: -0.51%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.0%
H: 1.01%
C: 0.97%
conference presentation
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer at the 2021 European Association of Urology Annual Congress
Published: 2021-06-28 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.73%
H: 7.15%
C: 5.45%
presentation europe prostate cancer phase 1 cancer phase 1b sabizabulin phase 2b
Veru to Present at the Jefferies Virtual Healthcare Conference
Published: 2021-05-25 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.73%
H: 1.93%
C: -0.97%
conference presentation
Veru Announces Acceptance of Two Abstracts for Presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Published: 2021-05-24 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.99%
H: 1.22%
C: 0.12%
presentation
Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021
Published: 2021-05-05 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.23%
H: 6.88%
C: -15.97%
presentation phase 2 positive cancer breast cancer her2+ her2- her2 metastatic breast cancer
Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
Published: 2021-04-21 (Crawled : 13:00) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.79%
H: 5.11%
C: 4.88%
presentation phase 2 cancer breast cancer her2+ her2- her2
Veru to Present at the Oppenheimer 31st Annual Healthcare Conference
Published: 2021-03-09 (Crawled : 14:25) - globenewswire.com
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 2.98%
H: 10.39%
C: 7.66%
conference presentation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.